Navigation Links
Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced its financial results for the first quarter ended March 31, 2009. Optimer reported a net loss for the first quarter of 2009 of $10.9 million, or $0.36 per share which was in line with the Company's expectations. This compares to a net loss for the first quarter of 2008 of $7.9 million, or $0.28 per share. Research and development expenses in the first quarter of 2009 were $8.8 million compared to $6.9 million in the first quarter of 2008. The increase is primarily due to an increase in clinical development and regulatory expenses related to Optimer's fidaxomicin and prulifloxacin programs.

As of March 31, 2009, Optimer held cash, cash equivalents and short-term investments of $62.6 million.

"We are off to a strong start in 2009," said Michael N. Chang, Ph.D., Optimer's President and CEO. "We announced plans to prepare a marketing application in Europe based on the results of the first fidaxomicin Phase 3 trial for Clostridium difficile infection. We also reported positive top-line results from the second prulifloxacin Phase 3 trial for the treatment of infectious diarrhea."

Recent Corporate Highlights

  • Announced plans to prepare a Marketing Authorization Application (MAA) for submission with the European Medicines Agency (EMEA) for approval of fidaxomicin as an oral treatment for Clostridium difficile infection (CDI) based on the results from the Company's first Phase 3 fidaxomicin trial.
  • Production patent for fidaxomicin issued by the United States Patent and Trademark Office.
  • Announced positive results from the second pivotal Phase 3 trial of prulifloxacin for the treatment of infectious diarrhea. The tri
    '/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
3. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
4. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
5. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
7. Idenix Pharmaceuticals Reports First Quarter Financial Results
8. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
9. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
10. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
11. Vanda Pharmaceuticals Reports First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... Va., April 1, 2008 Champions,Biotechnology, Inc. (OTC ... of advanced preclinical platforms and tumor specific data ... the appointment of new,Board of Directors members and ... prepares to expand its operations., Abba David ...
... April 1 Dr. Roger Kenneth,Hershline, PhD, MD, the ... the not-for-profit public charity CureHIV.us, announces today,that he is ... as the Grand Challenges in Global Health initiative. The,monies ... new drug and treatment,method, LiSAVIOR., This unique new ...
... 3-Minute Press,Show is a daily video program hosted ... Monday through Friday on:, http://www.wallst.net/wallst_tv/3_minute_press_show/index_wallst.php . WallSt.net,s ... executives on their company and most recent press ... insight into a company,s most,recent press release, and ...
Cached Biology Technology:Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 2Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 3Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 4Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 5Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 6Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 7Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 8Cure HIV Reaches Out to Foundation Community to Fund LiSAVIOR 2Featured Stocks on Today's Edition of WallSt.net's 3-Minute Press Show: BFNH, BKYI, RBCL 2Featured Stocks on Today's Edition of WallSt.net's 3-Minute Press Show: BFNH, BKYI, RBCL 3
(Date:10/15/2014)... SHELTON, Conn. , Oct. 15, 2014 NXT-ID, Inc. ... a biometric authentication company focused on the growing mobile commerce market ... NASDAQ MarketSite in Times Square on Monday October 13 th . ... with CTO David Tunnel and angel investor Mr. ... Gino Pereira , CEO of NXT-ID thanked his investors and employees ...
(Date:10/14/2014)... Ohio (Oct. 14, 2014)—It,s been millions of years since ... a team led by Ohio University scientists is breathing ... model airflow through dinosaur snouts. The research has important ... only breathe but to enhance the sense of smell ... ,nosy, animals," said Ohio University doctoral student Jason Bourke, ...
(Date:10/14/2014)... 2014 – Scientists from The Scripps Research Institute (TSRI) ... of Health (NIH) to lead an investigation of Lassa ... in Africa. The study aims to understand how Lassa ... while others survive the inflection. , "The ultimate ... of how Lassa fever virus causes disease and develop ...
Breaking Biology News(10 mins):Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... -- The world,s greatest wines are the result of a ... "terroir" -- a term often defined as the vineyard site, soil, ... emphasis on soil science in a symposium on Wednesday, Nov. 4 ... in two parts at the 2009 Annual Meetings of the American ...
... ALFRED, FLLaser labeling of fruit and vegetables is a new, ... is used to label, or "etch" information on produce, thereby ... been licensed for use on a variety of fruits and ... Pacific Rim countries. It has been been approved in Asia, ...
... COConsumer interest in new and diverse types of garlic ... growth of the "local foods" movement, interest in world ... demand for high-quality, locally grown garlic is increasing throughout ... the familiar white, "softneck" garlic (which is most often ...
Cached Biology News:Great wines come from great soils 2Laser etching safe alternative for labeling grapefruit 2Sustainably grown garlic 2Sustainably grown garlic 3
Request Info...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Maxi 14 Hybridization Oven. 14 bottle (35 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 medium bottles, pack of mesh, bottle gripper and d...
... The Neural Stem Cell Expansion Kit - Monolayer ... NSC expansion as a monolayer in a ... N-2 Plus Media Supplement, which has been optimized ... et al . (1996) Genes & Development ...
Biology Products: